Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

Routine Pre-Apheresis Markers As Predictors for Efficacy and Safety Outcomes Following CD19 CAR-T Cell Therapy - a Single Center Experience

Blood (2024) 144 (Supplement 1): 6548.

https://doi.org/10.1182/blood-2024-205736

Published: 2024

Journal Articles

Outcomes of Patients with Primary Central Nervous System Lymphoma Treated with Matrix Followed By High-Dose Chemotherapy and Autologous Stem Cell Transplant - a Multicentre, Retrospective Study

Adam Suleman, Michael Crump, Graeme Andrew McCrae Fraser, Robert Kridel, Sita D. Bhella, Chloe Yang, Vishal Kukreti, Stephen Ronan Foley, Tom Kouroukis, Amaris Balitsky, John Kuruvilla, Abi Vijenthira, Gwynivere A Davies, Anca Prica

Blood (2024) 144 (Supplement 1): 6281.

https://doi.org/10.1182/blood-2024-198044

Published: 2024

Journal Articles

Virtual Care Use for Patients with Hematologic Malignancies - a Natural Policy Experiment

Adam Suleman, Amy Zhihui Zhu, Anna Sinaiko, Anca Prica, Danielle Rodin

Blood (2024) 144 (Supplement 1): 3645.

https://doi.org/10.1182/blood-2024-198042

Published: 2024

Journal Articles

Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL

Sita D. Bhella, Katrina Hueniken, Rachel Aitken, Carmel Waldron, Michael Crump, John Kuruvilla, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Christine I Chen

Blood (2024) 144 (Supplement 1): 7791.

https://doi.org/10.1182/blood-2024-210635

Published: 2024

Journal Articles

Anthracycline Exposure and Breast Cancer Risk in Female Hodgkin Lymphoma Survivors

Karla Machlab, Vivian Aghanya, Lee Mozessohn, Michael Crump, Danielle Rodin, Ning Liu, Anca Prica

Blood (2024) 144 (Supplement 1): 4432.

https://doi.org/10.1182/blood-2024-204618

Published: 2024

Journal Articles

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Juan Pablo Alderuccio, Jahanzaib Khwaja, Sunwoo Han, Paola Ghione, Imran A. Nizamuddin, Aditi Saha, Ning Dong, Yucai Wang, Hua-Jay J Cherng, Seda S. Tolu, Nina Wagner-Johnston, Adam J. Olszewski, Natalie Grover, Jean L. Koff, Amrita Desai, Praveen Ramakrishnan Geethakumari, Tamara K Moyo, Jose Sandoval-Sus, Narendranath Epperla, Danielle S Wallace, Manali Kamdar, Alexey Danilov, Han W. Tun, Javier Munoz, Mayur S. Narkhede, Joanna M. Rhodes, Anca Prica, Andrea Kuhnl, Adrian Maraj, Jessica Okosun, Jeffery Smith, Wendy Osborne, Victoria Calvert, Dima el-Sharkawi, Ammar Hilali, Graham P. Collins, Kim Linton, Nagah Elmusharaf, Anna Santarsieri, Farheen Karim, Thomas Ollila, Sarah Monick, Iris Margalit Trutzer, Nilanjan Ghosh, Jones Can, Amy Ayers, Jacopo Calabrese De Feo, John Sharp, Rachel Treitman, Avyakta Kallam, Izel Okcu, Vismay Deshani, Firas Baidoun, Chathuri Abeyakoon, William Hann, Aisling Barrett, Brad Kahl, Julio C. Chavez, Kate Cwynarski

Blood (2024) 144 (Supplement 1): 571.

https://doi.org/10.1182/blood-2024-199781

Published: 2024

Journal Articles

Disparities in Clinical Trial Enrollment for Patients with Hematologic Malignancies - a 15-Year Princess Margaret Cancer Centre Experience

Adam Suleman, Anna Santiago, Tyler Pittman, Gilla Shapiro, Anca Prica, Sita D. Bhella, Heather Cole, Katherine Zeman, Gary Rodin, Susanna Sellmann, Amit Oza, Jennifer Jones, Rena M Conti, Meredith Rosenthal, Danielle Rodin

Blood (2024) 144 (Supplement 1): 401.

https://doi.org/10.1182/blood-2024-194613

Published: 2024

Journal Articles

Delays from Progression to Initial Appointment Occur with External Referrals for CAR T-Cell Therapy but Do Not Impact Survival

Sita D. Bhella, Katrina Hueniken, Osamah Jamal S. Jarallah, Melissa Teixeira Maltez, Rachel Aitken, Carmel Waldron, Michael Crump, John Kuruvilla, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Christine I Chen

Blood (2024) 144 (Supplement 1): 7581.

https://doi.org/10.1182/blood-2024-211007

Published: 2024

Journal Articles

Long Term Survivors (>15 years) of Multiple Myeloma: Patient Characteristics and Morbidity Burden

Rintu Sharma, Karla Alexandra Sanchez, Badraa Muharib, Esther Masih-Khan, Eshetu G. Atenafu, Harjot Vohra, Sita D. Bhella, Christine I Chen, Guido Lancman, Vishal Kukreti, Anca Prica, Donna E Reece, Rodger E Tiedemann, Suzanne Trudel, Chloe Yang, A. Keith Stewart

Blood (2024) 144 (Supplement 1): 7841.

https://doi.org/10.1182/blood-2024-208502

Published: 2024

Journal Articles

Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Donna E Reece, Giovanni Piza Rodriguez, Mariela A Pantoja, Eshetu G Atenafu, Darrell White, Irwindeep Sandhu, Julie Stakiw, Michael Sebag, Terrance Comeau, Kevin Song, Jean Roy, Martha L Louzada, Arleigh McCurdy, Vishal Kukreti, Suzanne Trudel, Anca Prica, Rodger E Tiedemann, Christine I Chen

Blood (2024) 144 (Supplement 1): 3376.

https://doi.org/10.1182/blood-2024-206247

Published: 2024

Journal Articles

A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

Tiana Kordbacheh, Anca Prica, Kelvin KW Chan, Mahmood Aminilari, Zharmaine Ante, Ning Liu, Inna Y Gong, Sita Bhella, Michael Crump, Abi Vijenthira, John Kuruvilla, Robert Kridel, Christine I Chen, Vishal Kukreti, Chloe Yang, Nauman Malik, David Hodgson, Danielle Rodin

Blood (2024) 144 (Supplement 1): 5134.

https://doi.org/10.1182/blood-2024-206375

Published: 2024

Journal Articles

Handgrip Strength - Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma

Steven Shih, Harjot Vohra, Anup Joseph Devasia, Sahar Khan, Eshetu Atenafu, Donna Reece, Suzanne Trudel, A. Keith Stewart, Sita D. Bhella, Vishal Kukreti, Chloe Yang, Rodger E. Tiedemann, Anca Prica, Eugene Leung, Christine I Chen

Blood (2024) 144 (Supplement 1): 4690.

https://doi.org/10.1182/blood-2024-198797

Published: 2024

Journal Articles

Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis

Inna Gong, Michael Crump, Anca Prica, Andrew Calzavara, Ning Liu, Danielle Rodin, David Hodgson, Lee Mozessohn, Matthew C. Cheung, John Kuruvilla

Blood (2024) 144 (Supplement 1): 3092.

https://doi.org/10.1182/blood-2024-206056

Published: 2024

Journal Articles

Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma

Davidson Zhao, Victoria Shelton, Inna Gong, Juan Rangel-Patiño, Ting Liu, Michael Hong, Vanessa Murad, Ur Metser, Anca Prica, Vishal Kukreti, Sita Bhella, Abi Vijenthira, Michael Crump, John Kuruvilla, Bernard Lam, Robert Kridel

Blood (2024) 144 (Supplement 1): 1606.

https://doi.org/10.1182/blood-2024-199677

Published: 2024

Journal Articles

Multiome Single Cell Analyses Identify a Distinct CD8+ T Cell Phenotype Linked to Treatment Response in PTLD

Tomohiro Aoki, Davidson Zhao, Noémie Lang, Yifan Yin, Ting Liu, Michael Hong, Johanna Regala, Troy Ketela, Anca Prica, John Kuruvilla, Pedro Farinha, Jan Delabie, Federico Gaiti, Kerry J. Savage, David W. Scott, Robert Kridel

Blood (2024) 144 (Supplement 1): 4385.

https://doi.org/10.1182/blood-2024-194926

Published: 2024

Journal Articles

Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance

Juan Rangel-Patiño, John Kuruvilla, Anca Prica, Robert Kridel, Sita D. Bhella, Vishal Kukreti, Jan Delabie, Abi Vijenthira, Manjula Maganti, Michael Crump

Blood (2024) 144 (Supplement 1): 2352.

https://doi.org/10.1182/blood-2024-210922

Published: 2024

Journal Articles

Subsequent Primary Malignancies in Patients with Indolent B Cell Non-Hodgkin Lymphoma Receiving Frontline Bendamustine Rituximab Therapy

Gwynivere A Davies, Anca Prica, Zharmaine Ante, Ning Liu, Gregory R Pond, Amaris K Balitsky, Lee Mozessohn

Blood (2024) 144 (Supplement 1): 3749.

https://doi.org/10.1182/blood-2024-211926

Published: 2024

Journal Articles

Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy

Chathuri Abeyakoon, Sita D. Bhella, Katrina Hueniken, Rachel Aitken, Carmel Waldron, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Christine I Chen, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Michael Crump, John Kuruvilla

Blood (2024) 144 (Supplement 1): 1695.

https://doi.org/10.1182/blood-2024-201189

Published: 2024

Journal Articles

Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis

Rintu Sharma, John Kuruvilla, Michael Crump, David Hodgson, Yangqing Deng, Abi Vijenthira, Vishal Kukreti, Robert Kridel, Rodger E Tiedemann, Sita Bhella, Chloe Yang, Anca Prica

Blood (2024) 144 (Supplement 1): 3082.

https://doi.org/10.1182/blood-2024-212184

Published: 2024

Journal Articles

Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada

Tiana Kordbacheh, Anca Prica, Kelvin KW Chan, Mahmood Aminilari, Zharmaine Ante, Ning Liu, Inna Y Gong, Sita D. Bhella, Michael Crump, Abi Vijenthira, John Kuruvilla, Robert Kridel, Christine I Chen, Vishal Kukreti, Chloe Yang, Nauman Malik, David Hodgson, Danielle Rodin

Blood (2024) 144 (Supplement 1): 2272.

https://doi.org/10.1182/blood-2024-201539

Published: 2024

NARROW

Routine Pre-Apheresis Markers As Predictors for Efficacy and Safety Outcomes Following CD19 CAR-T Cell Therapy - a Single Center Experience

Outcomes of Patients with Primary Central Nervous System Lymphoma Treated with Matrix Followed By High-Dose Chemotherapy and Autologous Stem Cell Transplant - a Multicentre, Retrospective Study

Virtual Care Use for Patients with Hematologic Malignancies - a Natural Policy Experiment

Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL

Anthracycline Exposure and Breast Cancer Risk in Female Hodgkin Lymphoma Survivors

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Disparities in Clinical Trial Enrollment for Patients with Hematologic Malignancies - a 15-Year Princess Margaret Cancer Centre Experience

Delays from Progression to Initial Appointment Occur with External Referrals for CAR T-Cell Therapy but Do Not Impact Survival

Long Term Survivors (>15 years) of Multiple Myeloma: Patient Characteristics and Morbidity Burden

Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

Handgrip Strength - Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma

Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis

Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma

Multiome Single Cell Analyses Identify a Distinct CD8+ T Cell Phenotype Linked to Treatment Response in PTLD

Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance

Subsequent Primary Malignancies in Patients with Indolent B Cell Non-Hodgkin Lymphoma Receiving Frontline Bendamustine Rituximab Therapy

Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy

Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis

Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only